Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer

The Rho-GTPase-activating protein, deleted in liver cancer-1 (DLC1), has been reported to be a tumor suppressor. However, the prognostic value of DLC1 in gastric cancer (GC) remains to be fully elucidated. Fluoropyrimidine-oxaliplatin (FP-LOHP) combination therapy has been widely used for the adjuva...

Descripción completa

Detalles Bibliográficos
Autores principales: SU, YUQI, LIN, LI, ZHANG, JINGWEN, JIANG, YAQI, PAN, CHANGQIE, SUN, LI, DUAN, JIANGMAN, LIAO, WANGJUN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581752/
https://www.ncbi.nlm.nih.gov/pubmed/26239822
http://dx.doi.org/10.3892/mmr.2015.4173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4581752/
https://www.ncbi.nlm.nih.gov/pubmed/26239822
http://dx.doi.org/10.3892/mmr.2015.4173

Ejemplares similares